Jonathan Anderman
Conseiller Juridique Général chez COMPASS THERAPEUTICS, INC.
Profil
Jonathan Anderman is currently the Secretary, Vice President & Head-Legal at Compass Therapeutics, Inc. Prior to this, he worked as the Global Commercial Counsel at Biogen, Inc. from 2020 to 2021 and as the Assistant General Counsel at Intarcia Therapeutics, Inc. from 2015 to 2018.
Anderman received his undergraduate degree from The Pennsylvania State University and his graduate degree from Boston University School of Law.
Postes actifs de Jonathan Anderman
| Sociétés | Poste | Début |
|---|---|---|
| COMPASS THERAPEUTICS, INC. | Conseiller Juridique Général | 01/08/2021 |
Anciens postes connus de Jonathan Anderman
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/08/2021 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/08/2018 |
Formation de Jonathan Anderman
| Boston University School of Law | Graduate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| COMPASS THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
